Fortrea Holdings Inc. (FTRE) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

14/25

Growth 5 Margin 2 Expansion 3 Platform 0 Financial 4

latest quarter score

Earnings Reports

14
Fortrea (FTRE) Q2 2026: Book-to-Bill Tops 1.06 as Biotech Pipeline Diversifies
July 29, 2026
13
Fortria (FTRE) Q1 2026: Book-to-Bill Reaches 1.15x as Biotech Pipeline Expands
May 05, 2026
12
Fortria (FTRE) Q4 2025: Book-to-Bill Hits 1.14x as Cost Discipline Unlocks $93M Net Savings
February 26, 2026
14
Fortrea (FTRE) Q3 2025: Book-to-Bill Rises to 1.13x as Biotech Win Rates Double
November 05, 2025
10
Fortria (FTRE) Q2 2025: $150M Cost Cuts Unlock Margin Stability Despite Biotech Win Rate Dip
August 06, 2025
9
Fortria (FTRE) Q1 2025: $150M Cost Reduction Plan Targets Margin Recovery Amid Oncology-Weighted Backlog
July 06, 2025
Fortrea (FTRE) Q4 2024: Book-to-Bill Hits 1.35 Amid Revenue Mix Challenges
March 03, 2025

Browse all companies